Collaborative Practice in the Management of Patients with Gastrointestinal and Pancreatic Neuroendocrine Tumors
Phoenix, AZ US
November 7, 2015
Learning Objectives
- Discuss how medical therapies fit within the wider range of treatment options available to patients with gastrointestinal or pancreatic neuroendocrine tumors
- Define the role of mTOR inhibitors and tyrosine kinase inhibitors in patients with recurrent disease
- Review the role of somatostatin analogs in patients with both functional and nonfunctional tumors
- Describe best practices for preventing choloecystitis and other adverse reactions associated with medical therapy for pNETs
- Recall key laboratory and imaging studies recommended for patients being trated for pNETs
JW Marriott Desert Ridge
5350 East Marriott Drive
Phoenix, AZ
85054
United States
Jennifer Ang Chan, MD, MPH
Robin Sommers, NP
Available Credit
- 1.00 AANP
- 0.67 Pharmacology
- 1.00 ACPE
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance
- 1.00 ANCC